InvitroCue, a Singapore-based biotech company, made its debut on the Australian Securities Exchange (ASX: IVQ) on Jan 27 2016, – just four years after its founding. The company, a spin-off from A*STAR, announced that it had raised an AUD 3.15 Million (SGD3.17 Million) on the ASX through a reverse takeover. On March 1st, 2016, they …
Download the InvitroCue Agreement PDF here: Agreement
09 March 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with London School of Hygiene & Tropical Medicine (London), recently signed an Agreement under which they started a collaboration using 3D in vitro technologies to establish leishmania spp. infection in vitro models. These technologies, when integrated, could offer a novel model for the in vitro …
Featured on The Edge Enterprise, The Week of 07 March 2016 Biotech entrepreneur Dr Steven Fang is no stranger to the start-up scene … Fang recently listed bio-analytics firm InvitroCue on the ASX, just four years after the company was founded. “What we’re doing today breaks almost all records. We took four years to build …
SINGAPORE and CHINA – March 05, 2016 – InvitroCue Pte Ltd and InvitroCue Biomedical Service Suzhou, a wholly owned subsidiary, today jointly announced the expansion of a cell-based laboratory facility in Suzhou to enhance the company’s current service offerings, and to meet current and future growth of the drug development in China. The expansion is …
Society of Toxicology 55th Annual Meeting and ToxExpo™ March 13-17, 2016 | New Orleans Ernest N. Morial Convention Center , LA Booth #1653| contact@invitrocue.com 15 February 2016, Singapore: Invitrocue Limited (ASX:IVQ) is honoured to participate in this year’s 55th Annual Meeting. 2016 promises to be an exciting year for InvitroCue. In only our second year of participation, …
15 February 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with TNO (the Netherlands), and Takara Bio Europe AB (Sweden), recently signed an Agreement under which they started a collaboration using different technologies to develop a model of non-alcoholic steatohepatitis (NASH). This collaborative project is part of TNO’s Early Research Program ‘Organ on-a-chip’, for which they …
Featured on Singapore News & Top Stories – The Straits Times 05 Feb 2016 By Lin Yangchen The liver is an important organ in drug testing because all drugs pass through it to be detoxified, a process that reduces or removes harmful substances from the body. By constructing a microscopic 3D scaffold to cultivate liver cells …
04 February 2016, Singapore and Sydney: Invitrocue Limited (ASX:IVQ) is pleased to announce Dr Steven Fang, the company’s Executive Director, shall hold an Investor Road Show beginning on 15 February. Selected journalists, analysts, institutional investors can get to know the company’s global expansion plan and attractive investment opportunity. Dr Fang will provide an update about InvitroCue’s …
CLEVELAND, OHIO and SINGAPORE – February 01, 2016 – ImageIQ, an innovative Imaging Software and Contract Research Organization supporting preclinical research and clinical trials, announced today an agreement with InvitroCue (“IVQ”), a Singapore-based provider of biomedical quantitative image analytic products and services, to enhance and accelerate preclinical research through the use of cloud-based image analysis …